Company intelligence / Profile preview

LIDDS AB

Uppsala, Sweden

Ownership: Private
Employees: ~10
Development stage: Phase 2

Overview

Liproca Depot met both primary and secondary endpoints in a Phase IIb study for intermediate-risk prostate cancer patients. The NanoZolid® technology has demonstrated validated drug release profiles in clinical trials with reduced systemic side effects[1][5][6]. Nanodotax has shown safety and tolerability in a Phase I study with positive immune biomarker responses[6].

Therapeutic areas: Oncology
Modalities: Small molecules (e.g., anti-androgens like 2-hydroxyflutamide)Chemotherapeutics (e.g., docetaxel)Immunotherapies (e.g., TLR9 agonists such as agatolimod)
Industry: Biotech

Drug pipeline

4 assets

2-hydroxyflutamide

3 more assets in the full pipeline.

Request access →

Partnerships

Johnson & Johnson Enterprise Innovation Inc. – R&D agreement to develop oncology products based on the NanoZolid platform.Puheng Pharma – License agreement for Liproca Depot in China.PharmIdea SIA – Collaboration focused on anti-cancer drugs and sterile formulations[4][6].

Beyond the preview

Go deeper on LIDDS AB.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LIDDS AB.

Explore the full profile